Cytarabine Injection, Solution
Product Images NDC 63323-120

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Cytarabine (NDC 63323-120). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cyt06 0001 01

FDA Label Image

Cyt06 0001 02

FDA Label Image

Cyt06 0001 03

This is a description of a drug called "SAETELILT Injection" with NDC 63323-120-20. It's a cytotoxic medication administered intravenously, intrathecally, and subcutaneously. It's available in a single-dose vial of 20 ml, containing 2 grams (100 mg per mL) of the medication. The drug is sterile, preservative-free, and requires storage at a controlled room temperature of 20° to 25°C (68° to 77°F) while protecting from light. The medication's usual dosage should be seen in the package insert, and any unused portion should be discarded. The last portion of the text is not readable.*

FDA Label Image

Cyt06 0001 04

This is a description of a medication called Cytarabine in injection form, used for intravenous, intrathecal, and subcutaneous use. It is available in a 20mL single-dose vial containing 2 grams per 20 mL (100 mg per mL) and is a cytotoxic agent. The usual dosage is indicated on the package insert. The container has NDC 63323-120-20 and is manufactured by Fresenius KaBI in Lake Zurich, IL. The medication should be stored at 20° to 25°C (68° to 77°F), protected from light, and discarded after use. The container closure is not made with natural rubber latex.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.